Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riess

Showing results (1291-1300 of 1,489) with videos related to

Pageof 149
Sort By:
Molecular Neurodegeneration|July 4, 2023
Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson diseaseYogesh Singh, Christoph Trautwein, Joan Romani, et al.
BMC Medical Genetics|August 17, 2018
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implicationsMarkus W Löffler, Julia Steinhilber, Franz J Hilke, et al.
Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Lung Cancer (Amsterdam, Netherlands)|March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.
American Journal of Human Genetics|March 13, 2012
Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disabilityJuliane Hoyer, Arif B Ekici, Sabine Endele, et al.
Scientific Reports|October 1, 2020
DJ-1 (Park7) affects the gut microbiome, metabolites and the development of innate lymphoid cells (ILCs)Yogesh Singh, Christoph Trautwein, Achal Dhariwal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, et al.
Neurobiology of Disease|July 20, 2011
Olfactory neuron-specific expression of A30P α-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stagesSilke Nuber, Elisabeth Petrasch-Parwez, Oscar Arias-Carrión, et al.
Human Mutation|September 15, 2004
Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7)Robert Hering, Karsten M Strauss, Xiao Tao, et al.
Thrombosis and Haemostasis|September 22, 2017
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI TrialAlok A Khorana, Saroj Vadhan-Raj, Nicole M Kuderer, et al.
Pageof 149

Showing results (1291-1300 of 1,489) with videos related to

Sort By:
Pageof 149
Molecular Neurodegeneration|July 4, 2023
Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson diseaseYogesh Singh, Christoph Trautwein, Joan Romani, et al.
BMC Medical Genetics|August 17, 2018
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implicationsMarkus W Löffler, Julia Steinhilber, Franz J Hilke, et al.
Oncology and Therapy|October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a VodcastBalazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Lung Cancer (Amsterdam, Netherlands)|March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.
American Journal of Human Genetics|March 13, 2012
Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disabilityJuliane Hoyer, Arif B Ekici, Sabine Endele, et al.
Scientific Reports|October 1, 2020
DJ-1 (Park7) affects the gut microbiome, metabolites and the development of innate lymphoid cells (ILCs)Yogesh Singh, Christoph Trautwein, Achal Dhariwal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, et al.
Neurobiology of Disease|July 20, 2011
Olfactory neuron-specific expression of A30P α-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stagesSilke Nuber, Elisabeth Petrasch-Parwez, Oscar Arias-Carrión, et al.
Human Mutation|September 15, 2004
Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7)Robert Hering, Karsten M Strauss, Xiao Tao, et al.
Thrombosis and Haemostasis|September 22, 2017
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI TrialAlok A Khorana, Saroj Vadhan-Raj, Nicole M Kuderer, et al.
Pageof 149